Prospective, Randomized, Open-Label, Controlled Study to Evaluate the Safety and Efficacy of Intensive Glycemic Control on Outcomes Following Liver Transplantation
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 164
- 试验地点
- 1
- 主要终点
- Rejection of Liver Transplant
研究概览
简要总结
Many but not all studies have shown improvement in morbidity and mortality with intensive glycemic management postoperatively. In this study, the investigators propose to determine whether improved glycemic control using intensive insulin treatment immediately postoperatively will improve outcomes in patients undergoing liver transplant using a prospective, controlled, randomized, parallel-group study design targeting two different glucose levels, 140 and 180 mg/dL.
详细描述
Many studies have shown improvement in morbidity and mortality with intensive glycemic management postoperatively. However, some recent studies have not been able to reproduce these benefits and have raised the issue of adverse consequences of hypoglycemia associated with intensive therapy. Our own data show an association of increased graft rejection proportional to postoperative glucose levels in patients who have undergone a liver transplant. Preliminary data suggest that this may improved by better glycemic control using the Glucose Management Service here at Northwestern.
In this study, we propose to determine whether improved glycemic control using intensive insulin treatment immediately postoperatively will improve outcomes in patients undergoing liver transplant using a prospective, controlled, randomized, parallel-group study design targeting two different glucose levels, 140 and 180 mg/dL. Postoperative glucose management with insulin will be supervised by the Glucose Management Service as is routine, with the only research aspect being the two different glucose targets and the outcome analysis with liver transplant rejection as the primary outcome and infections and hypoglycemia being the principle secondary outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Require Liver Transplantation
- •Age 18 - 80
- •Able to give informed consent personally or via a family member who has appropriate authorization to do so if patient unconscious.
- •Expected survival following transplantation for > 1 year.
- •Glucose level over 180 mg/dL postoperatively
排除标准
- •Inability of patient or family member to give informed consent
- •Not expected to survive for > 1 year following liver transplantation.
- •Previous liver transplantation
- •Acute liver failure
- •Living related donor
研究组 & 干预措施
140 Group
Insulin treatment to target blood glucose at 140 mg/dl
干预措施: Insulin (Drug)
180 Group
Insulin treatment to target blood glucose at 180 mg/dl
干预措施: Insulin (Drug)
结局指标
主要结局
Rejection of Liver Transplant
时间窗: within 1 year of transplantation
Liver transplant rejection determined by either biopsy or clinical criteria (\>2x transaminases, clinical decision, treatment with high dose steroids and other anti-rejection medications
次要结局
- Infection Rates(Within 1 year following transplantation)
- Rehospitalization Rates(Within 1 year following transplantation)
- Overall Graft Survival at 1 Year(1 year following transplantation)
- Death Within 1 Year(1 year)
- Hypoglycemia(Within first 3 days following transplantation)
研究者
Mark Molitch
Professor of Medicine
Northwestern University
